XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs.

被引：0
|
作者：
Etchin, Julia [1 ]
Berezovskaya, Alla [1 ]
Conway, Amy S. [1 ]
Galinsky, Ilene A. [1 ]
Stone, Richard M. [1 ]
Baloglu, Erkan [2 ]
Senapedis, William [2 ]
Landesman, Yosef [2 ]
Kauffman, Michael [2 ]
Shacham, Sharon [2 ]
Wang, Jean C. Y. [3 ]
Look, A. Thomas [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Karyopharm Therapeut Inc, Newton, MA USA
[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
39
引用
收藏
页码：60 / 60
页数：1
相关论文
共 14 条
  • [1] KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
    Etchin, J.
    Berezovskaya, A.
    Conway, A. S.
    Galinsky, I. A.
    Stone, R. M.
    Baloglu, E.
    Senapedis, W.
    Landesman, Y.
    Kauffman, M.
    Shacham, S.
    Wang, J. C. Y.
    Look, A. T.
    LEUKEMIA, 2017, 31 (01) : 143 - 150
  • [2] KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
    J Etchin
    A Berezovskaya
    A S Conway
    I A Galinsky
    R M Stone
    E Baloglu
    W Senapedis
    Y Landesman
    M Kauffman
    S Shacham
    J C Y Wang
    A T Look
    Leukemia, 2017, 31 : 143 - 150
  • [3] The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
    Verbeke, Delphine
    Demeyer, Sofie
    Prieto, Cristina
    de Bock, Charles E.
    De Bie, Jolien
    Gielen, Olga
    Jacobs, Kris
    Mentens, Nicole
    Verhoeven, Bronte Manouk
    Uyttebroeck, Anne
    Boeckx, Nancy
    De Keersmaecker, Kim
    Maertens, Johan
    Segers, Heidi
    Cools, Jan
    CLINICAL CANCER RESEARCH, 2020, 26 (21) : 5747 - 5758
  • [4] Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma
    Turner, Joel G.
    Dawson, Jana L.
    Cubitt, Christopher L.
    Baluglo, Erkan
    Grant, Steven
    Dai, Yun
    Shain, Kenneth H.
    Dalton, William S.
    Shacham, Sharon
    Senapedis, William
    Sullivan, Daniel M.
    BLOOD, 2015, 126 (23)
  • [5] Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML
    Etchin, Julia
    Berezovskaya, Alla
    Conway, Amy Saur
    Chen, Weihsu Claire
    Baloglu, Erkan
    Landesman, Yosef
    Senapedis, William
    Ellis, Joel
    McCauley, Dilara
    Stone, Richard M.
    Galinsky, Ilene
    DeAngelo, Daniel J.
    Kauffman, Michael
    Shacham, Sharon
    Wang, Jean C. Y.
    Look, A. Thomas
    BLOOD, 2015, 126 (23)
  • [6] KPT-8602 IS A SECOND-GENERATION XPO1 INHIBITOR WITH IMPROVED IN VIVO TOLERABILITY AND POTENT IN VIVO ACTIVITY AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA
    De Bie, J.
    Neggers, J.
    Dagklis, A.
    Vercruysse, T.
    Gielen, O.
    Baloglu, E.
    Senapedis, W.
    Shacham, S.
    Landesman, Y.
    Uyttebroeck, A.
    Boeckx, N.
    Cools, J.
    Daelemans, D.
    HAEMATOLOGICA, 2016, 101 : 350 - 350
  • [7] KPT-8602 is a second-generation XPO1 inhibitor with improved in vivo tolerability that demonstrates potent acute lymphoblastic leukemia activity
    Daelemans, Dirk
    Neggers, Jasper Edgar
    De Bie, Jolien
    Jacquemyn, Maarten
    D'Hoore, Astrid
    Vanstreels, Els
    Baloglu, Erkan
    Landesman, Yosef
    Shacham, Sharon
    Senapedis, William
    Dagklis, Antonis
    Vercruysse, Thomas
    Cools, Jan
    CANCER RESEARCH, 2016, 76
  • [8] The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-?B/NLRP3 Pathway
    Liu, Shuhan
    Wang, Shengxiang
    Gu, Runze
    Che, Na
    Wang, Jing
    Cheng, Jinbo
    Yuan, Zengqiang
    Cheng, Yong
    Liao, Yajin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] XPO1抑制剂KPT-8602对U937细胞增殖和凋亡的影响
    肖晓慧
    李益清
    黄克智
    谢双锋
    肖洁
    马丽萍
    尹松梅
    聂大年
    中山大学学报(医学版), 2019, 40 (01) : 37 - 45
  • [10] Selinexor or KPT-8602 mediated XPO1 inhibition synergizes with dexamethasone to repress convergent pathways in the mTORC1 signaling network and drive cell death in multiple myeloma
    Argueta, Christian
    Kashyap, Trinayan
    Klebanov, Boris
    Chang, Hua
    Friedlander, Sharon
    Baloglu, Erkan
    Landesman, Yosef
    Lee, Margaret
    Gardner, Humphrey
    Shacham, Sharon
    Senapedis, William
    CANCER RESEARCH, 2017, 77
12